Ferring Pharmaceuticals Inc. has entered into an agreement to market Euflexxa, a novel, non-avian-derived biologic formulation of hyaluronic acid for the amelioration of knee pain due to osteoarthritis. This agreement forms part of a broader transaction whereby the Ferring Group acquired the global biologics manufacturing business of Savient Pharmaceuticals, Inc., including the worldwide rights to Euflexxa.
“This agreement represents an additional specialty marketing opportunity that expands our product line beyond infertility,” Wayne Anderson, president of Ferring Pharmaceuticals said adding, “It is in keeping with our corporate strategy of niche marketing specialty products with manageable physician prescribing audiences.”
Euflexxa is the first and only non-avian-derived biologic formulation of hyaluronic acid approved in the US for osteoarthritis of the knee. Under the agreement, Ferring and Savient, the developers of the product, will jointly market Euflexxa, which is expected to launch in Q4 2005. Ferring will be forming a specialist field force for this purpose.